WG
MLTX icon

Winton Group’s MoonLake Immunotherapeutics MLTX Stock Holding History

Winton Group’s Portfolio MLTX Stock Details MLTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$302K Sell
15,500
-170
-1% -$3.08K 0.01% 887
2026
Q1 		$292K Buy
+15,670
New +$260K 0.01% 869
2025
Q3 		– Sell
-12,565
Closed -$593K – 915
2025
Q2 		$593K Buy
+12,565
New +$512K 0.03% 550

Other funds holding MLTX

BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
WAM
Weiss Asset Management Boston, Massachusetts $9.54B AUM 55.06% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Winton Group's MLTX Position: Q2 2026 in Review

Winton Group reduced its MoonLake Immunotherapeutics (MLTX) stake by 1.1% in Q2 2026, selling an estimated $3.08K and leaving 15,500 shares worth $302K. The position accounts for 0.01% of the portfolio, ranked #887.

Winton Group first reported a position in MLTX in Q2 2025 and has held it in 3 quarters since. The position peaked at $593K in Q2 2025. 172 funds tracked by Wall St. Rank hold MLTX as of Q2 2026.

  • Winton Group held 15,500 shares of MoonLake Immunotherapeutics worth $302K as of Q2 2026.
  • Winton Group sold 170 MoonLake Immunotherapeutics shares in Q2 2026, an estimated $3.08K.
  • MoonLake Immunotherapeutics made up 0.01% of Winton Group's portfolio in Q2 2026, its #887 holding.
  • Winton Group first reported a position in MoonLake Immunotherapeutics in Q2 2025 and has held it in 3 quarters since.
  • Winton Group's MoonLake Immunotherapeutics position peaked at $593K in Q2 2025.
  • 172 funds tracked by Wall St. Rank held MoonLake Immunotherapeutics as of Q2 2026.

Based on Winton Group's 13F filing for Q2 2026, filed 7 Aug 2026.